Lapatinib (Tykerb) plus letrozole (Femara) or letrozole alone for postmenopausal hormone receptor-positive metastatic breast cancer

P and T

Volumn 34, Issue 2, 2009, Pages 102-

  Johnston, Stephen ^a   Arteaga, Carlos ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; LAPATINIB; LETROZOLE; PLACEBO;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE;

EID: 62149092260     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)